Warnex Inc.

Warnex Inc.

April 23, 2007 07:00 ET

Warnex successfully passes FDA inspection of its bioanalytical facilities

LAVAL, QC, April 23 - Warnex Inc. (TSX: WNX) today reported the
favourable outcome from an inspection of its facilities performed by the U.S.
Food and Drug Administration (FDA) and completed on April 6, 2007.

The FDA inspected and reviewed Warnex's bioanalytical laboratories and
their quality control systems, as well as several client-specific studies,
during the recent audit. Warnex is compliant with FDA regulations and there
were no major observations requiring any corrective action.

"We are pleased to have once again successfully passed an FDA audit. This
achievement demonstrates the ongoing quality of our work at all levels of our
organization," said Mark Busgang, President and CEO of Warnex.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting
public health by providing laboratory services to the pharmaceutical and
healthcare sectors. Warnex's analytical services division provides
pharmaceutical and biotechnology companies with a variety of quality control
services, including traditional chemistry, chromatography, microbiology,
method development and validation, and stability studies. Warnex's
bioanalytical services group specializes in bioequivalence and bioavailability
studies for clinical trials. Warnex's medical laboratories division focuses on
genetic and biochemical testing for the healthcare industry and has extensive
expertise in genetic testing for human identification, molecular diagnostics,
and pharmacogenetics.


Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, integration of acquisitions, manufacturing and
laboratory facilities, suppliers, key employees, key customers and business
partners, financial resources and credit risk, government regulations, foreign
currency risk, volatility of share price, strategic alternatives for the
pathogen detection division, and other important factors that could cause
actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and
Uncertainties in the Management's Discussion and Analysis in the 2006 Annual
Report, which can be found at www.sedar.com. Consequently, actual results may
differ materially from the anticipated results expressed in these
forward-looking statements.

Contact Information